A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Preclinical findings suggest that the inhibition of NMDA glutamatergic neurotransmission may have beneficial effects in the treatment of cocaine dependence. We hypothesized that memantine, a low potency, uncompetitive NMDA receptor antagonist, would be safe and effective in the treatment of cocaine dependence, particularly in preventing relapse to cocaine use in abstinent individuals. Cocaine dependent patients (N =112) were enrolled. The trial began with a 2-week placebo lead-in period during which patients received high-value voucher contingency management to induce abstinence. Participants were then randomized to receive either memantine 20 mg bid (N=39) or placebo (N=42) for 12-weeks in combination with individual relapse-prevention therapy. The randomization was stratified by abstinence status during the lead-in period. The primary outcome was the weekly proportion of days of cocaine use. There were no significant differences in cocaine use outcome between the groups treated with memantine versus placebo. Thus, the efficacy of memantine 40 mg/d for the treatment of cocaine dependence was not supported. Urine-confirmed abstinence during the lead-in period was achieved by 44% of participants, and was a strong predictor of subsequent cocaine abstinence during the trial. This suggests that this clinical trial design, an intensive behavioral intervention during a lead-in period, resolves cocaine dependent patients into two subgroups, one that rapidly achieves sustained abstinence and may not need a medication, and another that displays persistent cocaine use and would most likely benefit from a medication to help induce abstinence. Targeting the latter subgroup may advance medication development efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Incentives Improve Outcome in Outpatient Behavioral Treatment of Cocaine Dependence
Higgins, S. T. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070060011 · Cited by 806
Psychomotor stimulant addiction: a neural systems perspective
Everitt, B. J., & Wolf, M. E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03312.2002 · Cited by 700
Martinez, D., Narendran, R., Foltin, R. W., Slifstein, M., Hwang, D.-R., Broft, A., Huang, Y., Cooper, T. B., Fischman, M. W., Kleber, H. D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.4.622 · Cited by 351
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243 · cited 2×
“Some clinical trials have suggested that medications have greater efficacy in more homogeneous subsets of patients, such as those differing in the baseline level of use (Bisaga et al., 2006; Elkashef et al., 2008; Grabowski et al., 2001; Shoptaw et al., 2008) or the existence of comorbid conditions (Anderson et al.”
BackgroundModafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · cited 2×
“Some clinical trials have suggested that medications have greater efficacy in more homogeneous subsets of patients, such as those differing in the baseline level of use (Bisaga et al., 2006; Elkashef et al., 2008; Grabowski et al., 2001; Shoptaw et al., 2008) or the existence of comorbid conditions (Anderson et al.”
BackgroundLevodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform
Schmitz, J. M., Mooney, M. E., Moeller, F. G., Stotts, A. L., Green, C., & Grabowski, J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.004 · Cited by 124
Cited by
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 298
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186
Self-citationPharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Dakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
“receptor involved in neural plasticity,(3) consistently disrupts the reinforcing effects of cocaine in rodents,(8-10) comparable modulators, such as memantine and D-cycloserine (DCS), have proven ineffective in humans in both laboratory and clinical settings.(11-13)”
Self-citation
Metadata
- Authors
- Bisaga, A., Aharonovich, E., Cheng, W. Y., Levin, F. R., Mariani, J. J., Raby, W. N., & Nunes, E. V.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2010-09-01
- Volume
- 111
- Issue
- 1-2
- Pages
- 97-104
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2082876871
- Cited by
- 59
- References
- 8
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2010.04.006
- The paper
- Bisaga, A., Aharonovich, E., Cheng, W. Y., Levin, F. R., Mariani, J. J., Raby, W. N., & Nunes, E. V. (2010). A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2010.04.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.